Niosomes (nonionic surfactant-based vesicles) containing rifampicin were prepared using various nonionic surfactants of sorbitan ester class and cholesterol in 50:50 percent mol fraction ratio. The drug-entrapped vesicles were characterized for their shape, size, drug entrapment efficiency and in vitro release rate. On the basis of in vitro characterization, the niosomes showing maximum entrapment and minimum release rate were selected for in vivo performance evaluation. Cumulative percent doses of rifampicin recovered in thoracic lymph following intravenous and intraperitoneal administrations of free rifampicin solution and niosome-encapsulated rifampicin were compared. The study revealed that effective compartmentalisation of the drug took place in the lymphatic system following intraperitoneal administration of niosome-encapsulated rifampicin. Thus rifampicin encapsulated in niosomes could successfully be used for treatment of tuberculosis along lymphatic system.
For effective chemotherapy, an optimal concentration of clinical failure. Rifampicin also has various side effects, chemotherapeutic agent must reach the affected tissue/(s) such as immunological disturbances, rheumatoid or lupoid and remain there for a required period of time. Since a syndromes, allergic rashes, eosinophilia, leucopoenia, number of chemotherapeutic agents are cytotoxic, the jaundice and other hepatotoxic manifestations 7 presence of drug in the non-diseased tissue/(s) can lead to serious side effects. Encapsulation of drug in vesicular Niosomes or nonionic surfactant-based vesicles, formed structures can be predicted to prolong the existence of when a mixture of cholesterol and surfactant is hydrated, the drug in the systemic circulation and thus enhance can entrap solutes, are osmotically active and stable and penetration into target tissue, and perhaps reduce toxicity are similar in terms of their physical properties to if selective uptake can be achieved 1 .
liposomes (lipid-based vesicles). Niosomes may overcome the problems associated with liposomes, one of which The lymphatic system is the second most susceptible site relates to the chemical instability of the constituent for tuberculosis and ranks after lungs. Targeting of drugs phospholipids. Due to their predisposition to oxidative to the lymphatic system is very difficult due to its peculiar degradation, phospholipids must be stored and handled in . nature and position, but by using various routes of administration such as intramuscular 2, 3 , subcutaneous and intraperitoneal [4] [5] [6] , significant enhancement in the lymphatic delivery of chemotherapeutic agents has been reported.
Rifampicin is frequently used in the treatment of tuberculosis, a disease widely prevalent, especially in Third World countries, and requiring high dose treatment over a period of 4-6 mo. The causative organism is known to develop resistance if drug blood levels remain below the minimum effective concentration, leading to *For correspondence E-mail: jaincp66@yahoo.co.in nitrogen atmosphere. The cost and variable purity of natural phospholipids also militate against adoption of liposomes as drug delivery vesicles [8] [9] [10] [11] [12] [13] . Niosomes have been used for improving the stability of entrapped drug 14 ; for detection of tumours 15 ; and to modify the tissue distribution of entrapped harmine 16 , influenza antigen 17 , nimesulide 18 , methotrexate 6,10 , doxorubicicin 11 , sodium stibogluconate 13 , diclofenac sodium 9 and rifampicin 19 .
MATERIALS AND METHODS
Rifampicin was procured from Lupin Laboratories Ltd., Aurangabad. Triton-X-100 was procured from Himedia Laboratories Pvt. Ltd., Mumbai. Span-20, Span-40, Span- www.ijpsonline.com 60, Span-80 and Span-85 were procured from Fluka, Germany. Cholesterol was procured from Sigma, St. Louis, MO., USA. Diethyl ether and methanol procured from E. Merck, Mumbai, were used as received; and other reagents were of analytical grade, procured from Qualigens, the chemical division of Glaxo India Ltd., Mumbai.
Preparation of niosomes:
The niosomes were prepared by the method reported by Azmin et al. 10 Surfactants and cholesterol (150 µmol) in reported HPLC method.
In vivo lymphatic uptake study:
The preparation with the composition of Span-85 and cholesterol in 50:50 percent mol fraction ratio was selected for in vivo performance evaluation study. Twenty-four Wistar rats of either sex, each weighing about 250 g, were divided into four groups of six each.
All animal experiments performed in the present study were approved by the IAEC. The animals were given an oral dose of soyabean oil (4.0 ml/kg) and 1 h later 50:50 percent mol fraction ratio were dissolved in 10 ml anaesthetised with an injection of urethane (1.2 g/kg). diethyl ether in a 50 ml round-bottom flask, and ether was Animals were then dissected and the thoracic duct was removed at an ambient temperature (30°) under reduced cannulated as described by Bollman et al. 21 The left pressure in a rotatory flash evaporator (Buchi Model, femoral artery and the urinary bladder were also Yorco, New Delhi). The dried film of surfactant was cannulated. First and second group animals were hydrated with occasional shaking for 15 min at 70° on administered 0.5 ml of plain drug solution containing 2 mg water bath with 5 ml aqueous phase (phosphate buffer rifampicin (calculated at the dose level 8 mg/kg) based on saline, pH 7.4) containing 25 mg rifampicin. This human dose intraperitoneally and intravenously suspension was then sonicated for 3 x 30 s to form respectively, while each animal of the third and fourth unilamellar niosomes.
group was administered with 0.5-0.7 ml of niosomal formulation (containing 2 mg rifampicin) intravenously and The resultant aqueous dispersions of rifampicin-bearing intraperitoneally respectively. The animals were kept at niosomes were dialysed exhaustively in Cuprophane 37±2° in a supine position. Fluid balance was maintained dialysis tubing against phosphate buffer saline (pH 7.4) to by constant infusion of saline at the rate of 4 mg/h/kg. separate the unentrapped rifampicin from the niosomeLymph was collected periodically over 6 h duration of the entrapped rifampicin. study. At the end of 6 h, the animals were sacrificed and the peritoneal cavity was rinsed thrice to recover In vitro characterization of niosomes: unabsorbed formulation. All estimations of rifampicin were The shape and size of the niosomes was studied by an done by the HPLC method reported by Oldfied 20 optical microscope using a pre-calibrated ocular eye piece. The entrapment efficiencies were determined by
RESULTS AND DISCUSSION
complete dissolution of vesicles using Triton-X-100. The entrapped rifampicin was estimated by digesting a definite The niosomes were observed as spherical vesicles with quantity of the niosomal suspension with 10% Triton-X-100 smooth surface. The vesicles were discrete and separate for 5 min and centrifuging the resulting solution to get with no aggregation or agglomeration. The size of the clear supernatant. The supernatant was suitably diluted vesicles was uniform and independent of surfactant, as . using phosphate buffer saline and rifampicin estimated using HPLC method reported by Oldfied et al. 20 The in vitro release rate was determined using Nesselers cylinder of 50 ml, one end of which was sealed using a circular disc of cellophane membrane (Spectrapore 0.4 µm). Measured amount of niosomes were placed in the cylinder. The cylinder was placed in 500 ml of phosphate buffer saline, pH 7.4, maintained at 37° and aliquots were withdrawn at intervals of 24 h for 5 d. At each sampling time, the volume of receptor compartment was maintained with an equal volume of phosphate buffer saline, pH 7.4. The drug in withdrawn samples was estimated by the vesicles of all the surfactants were sonicated to same size. The average size of the vesicles is reported in Table 1 .
The percent (of initially taken drug) of drug estimated to be entrapped was noted to decrease progressively for various sorbitan esters used in the order of Span 85>Span-80>Span-60>Span-40>Span-20 (Table 1) . This may be explained on the basis of chemical nature of the surfactants. The corresponding HLB values for these surfactants are 1.8, 4.3, 4.7, 6.7 and 8.6 respectively. The lower the HLB number, the more lipophilic is the compound. Thus Span-85 has the highest lipophilicity; The cumulative amount of rifampicin transferred to the thoracic lymph following intravenous and intraperitoneal administration of free drug and niosome-encapsulated drug is shown in fig. 1 . As shown in the figure, the maximum lymph concentration achieved was 46.2% of the administered dose, when the drug was administered in the niosomal formulation via intraperitoneal route; while only 7.3% of the administered dose was recovered from the thoracic lymph when the niosomal formulation was solution via intraperitoneal and intravenous route respectively. Thus following intraperitoneal administration, effective compartmentalisation of the drug took place in the lymph system. The system thus holds promise for the use in the treatment of tuberculosis along the lymphatic system. However, the initial dose requirement and subsequent supply of drug from niosomes required to achieve the minimum effective concentration need further study. www.ijpsonline.com
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